Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases
- 384 Downloads
Objective of this study was to compare the assay characteristics of a new fecal calprotectin rapid test with an enzyme-linked immunosorbent assay (ELISA). The second aim was to assess the potential of measuring fecal calprotectin as screening method for intestinal inflammation and colorectal malignancies.
Patients and methods
One hundred forty patients with lower gastrointestinal symptoms referred to colonoscopy provided fecal samples (56, control group; 18, diverticulosis; 29, colorectal adenoma; 8, colorectal carcinoma (CRC); 18, active inflammatory bowel disease (IBD); 11, intestinal infections). Feces were analyzed by two assay methods.
Compared to the control group (median 25.8 µg/g), calprotectin levels were significantly increased in adenoma (66.3 µg/g), CRC (164 µg/g), intestinal infections (306 µg/g), and active IBD (797 µg/g). An adequate diagnostic accuracy could be found for active IBD with a sensitivity, specificity, and an area under the curve (AUC) of 100%, 79%, and 0.955 (ELISA) vs. 89%, 80%, and 0.896 (rapid test). Similar results were obtained for CRC (100%, 79%, 0.922 vs. 100%, 80%, 0.948) whereas in adenomas a low sensitivity, specificity, and AUC of 55%, 79%, and 0.686 vs. 52%, 80%, and 0.666 were found for fecal calprotectin.
Both fecal calprotectin assays are effective in identifying active IBD and CRC but lack analytical sensitivity in separating CRC from adenoma as well as adenoma from the control group. The new calprotectin rapid test is a convenient method for assessing the calprotectin level in an outpatient setting. Henceforth, it provides a precondition for the fecal calprotectin method to challenge fecal occult blood testing in further evaluations.
KeywordsFecal calprotectin Inflammatory bowel disease Carcinoma Adenoma Diverticulosis
The authors gratefully acknowledge the excellent assistance of Prof. W. Zoller, MD, A. Schreiber, MD, (Katharinenhospital), E. Fröhlich, MD, M. Schmidt, MD, (Karl-Olga-Hospital), Prof. E. Stange, MD, (Robert-Bosch-Hospital), H. Gölkel, MD, Th. Bühler MD, Prof. B. Klump, MD, K. Teubner, MD, D. Vogler, MD, A. Maier, MD, and A. Mühlhöfer, MD, in recruiting patients and kindly providing samples.
- 1.Gearry R, Barclay M, Florkowski C, George P, Walmsley T (2005) Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. NZMJ 118:1444–1451Google Scholar
- 2.Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F et al (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49:861–867PubMedCrossRefGoogle Scholar
- 4.Gaya D, Mackenzie JFR (2002) Faecal calprotectin: a bright future for assessing disease activity in Crohn’s disease. Q J Med 95:557–558Google Scholar
- 23.Fagherol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I (1990) Calprotectin (the L1 leucocyte protein). In: Smith VL, Dedman JR (eds) Stimulus response coupling: the role of intracellular calcium-binding proteins. CRC, Boca Raton, pp 187–210Google Scholar
- 25.Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF et al (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol 50:113–123Google Scholar
- 29.Tibble JA, Sigthorsson G, Foster R et al (1998) NSAID enteropathy: a new simple diagnostic test. Gut 42:142Google Scholar
- 36.Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH (2004) Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53:1329–1333PubMedCrossRefGoogle Scholar